Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression

Neuro-Oncology

Volumn 16, Issue 5, 2014, Pages 662-670

  Reyes Botero, German ^a   Dehais, Caroline ^a   Idbaih, Ahmed ^a,b   Martin Duverneuil, Nadine ^a   Lahutte, Marion ^c   Carpentier, Catherine ^b   Letouzé, Eric ^d   Chinot, Olivier ^e   Loiseau, Hugues ^f   Honnorat, Jerome ^g,h   Ramirez, Carole ⁱ   Moyal, Elisabeth ^j   Figarella Branger, Dominique ^e,k   Ducray, François ^g,h   Desenclos, Christine ^l   Sevestre, Henri ^l   Menei, Philippe ^l   Michalak, Sophie ^l   Al Nader, Edmond ^l   Godard, Joel ^l   Viennet, Gabriel ^l   Carpentier, Antoine ^l   Eimer, Sandrine ^l   Dam Hieu, Phong ^l   Quintin Roué, Isabelle ^l   Guillamo, Jean Sebastien ^l   Lechapt Zalcman, Emmanuelle ^l   Kemeny, Jean Louis ^l   Verrelle, Pierre ^l   Faillot, Thierry ^l   Gaultier, Claude ^l   Tortel, Marie Christine ^l   Christov, Christo ^l   Le Guerinel, Caroline ^l   Aubriot Lorton, Marie Hélène ^l   Ghiringhelli, Francois ^l   Berger, François ^l   Lacroix, Catherine ^l   Parker, Fabrice ^l   Dubois, François ^l   Maurage, Claude Alain ^l   Gueye, Edouard Marcel ^l   Labrousse, Francois ^l   Jouvet, Anne ^l   Bauchet, Luc ^l   Rigau, Valérie ^l   Beauchesne, Patrick ^l   Vignaud, Jean Michel ^l   Campone, Mario ^l   Loussouarn, Delphine ^l   Fontaine, Denys ^l   Vandenbos, Fanny ^l   Campello, Chantal ^l   Roger, Pascal ^l   Fesneau, Melanie ^l   Heitzmann, Anne ^l   Delattre, Jean Yves ^l   Elouadhani, Selma ^l   Mokhtari, Karima ^l   Polivka, Marc ^l   Ricard, Damien ^l   Levillain, Pierre Marie ^l   Wager, Michel ^l   Colin, Philippe ^l   Diebold, Marie Danièle ^l   Chiforeanu, Dan ^l   Vauleon, Elodie ^l   Langlois, Olivier ^l   Laquerriere, Annie ^l   Motsuo Fotso, Marie Janette ^l   Peoc'H, Michel ^l   Andraud, Marie ^l   Mouton, Servane ^l   Chenard, Marie Pierre ^l   Noel, Georges ^l   Desse, Nicolas ^l   Soulard, Raoulin ^l   Amiel Benouaich, Alexandra ^l   Uro Coste, Emmanuelle ^l   Dhermain, Frederic ^l   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c HÔPITAL D'INSTRUCTION DES ARMÉES ROBERT PICQUÉ   (France)

^d Cartes d'Identité des Tumeurs Program   (France)

^e TIMONE HOSPITAL   (France)

^f HÔPITAL PELLEGRIN   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h LYON NEUROSCIENCE RESEARCH CENTER   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k AIX MARSEILLE UNIVERSITY   (France)

^l AP HM Hôpital de la Timone Service d'Anatomie Pathologique et de Neuropathologie ^*

more..

Author keywords

1p19q co deletion; Anaplastic oligodendroglioma; IDH mutation; Magnetic resonance imaging; SNP array

Indexed keywords

ANGIOPOIETIN 2; CONTRAST MEDIUM; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ISOCITRATE DEHYDROGENASE 1; VASCULOTROPIN A; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME DELETION 1P 19Q; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FRANCE; FRONTAL LOBE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; MALE; MIDDLE AGED; MOLECULAR GENETICS; MULTICENTER STUDY; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PREDICTIVE VALUE; SEQUENCE ANALYSIS; SIGNAL PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR LOCALIZATION; TUMOR VOLUME; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME 9; GENETICS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE EXPRESSION; GENOMIC INSTABILITY; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGODENDROGLIOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84899457632     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not235     Document Type: Article

References (55)

1. Ricard D Idbaih A Ducray F Lahutte M Hoang-Xuan K Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984-1996
2. Cairncross G Wang M Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-Term results of RTOG 9402. J Clin Oncol. 2013;31:337-343
3. van Den Bent MJ Brandes AA Taphoorn MJ et al. Adjuvant procarbazine lomustine and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-Term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-350
4. Labussiere M Idbaih A Wang XW et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23): 1886-1890
5. Jenkinson MD du Plessis DG Smith TS Joyce KAWarnke PCWalker C. Histological growth patterns and genotype in oligodendroglial tumours: Correlation with MRI features. Brain. 2006;129:1884-1891
6. Kim JW Park CK Park SH et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2011;82:224-227
7. Laigle-Donadey F Martin-Duverneuil N Lejeune J et al. Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology. 2004;63:2360-2362
8. Megyesi JF Kachur E Lee DH et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res. 2004;10: 4303-4306
9. Zlatescu MC TehraniYazdi A Sasaki H et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;61:6713-6715
10. Carrillo JA Lai A Nghiemphu PL et al. Relationship between tumor enhancement edema IDH1 mutational status MGMT promoter methylation and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33:1349-1355
11. Diehn M Nardini C Wang DS et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105:5213-5218
12. Ellingson BM Lai A Harris RJ et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013;34:533-540
13. Lai A Kharbanda S Pope WB et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29:4482-4490
14. Idbaih A Ducray F Dehais C et al. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One. 2012;7:e45950
15. Louis DN Ohgaki H Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114: 97-109
16. Ducray F de Reynies A Chinot O et al. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer. 2010;9:234
17. Sanson M Marie Y Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154
18. Verhaak RG Hoadley KA Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA IDH1 EGFR and NF1. Cancer Cell. 2010;17: 98-110
19. Subramanian A Tamayo P Mootha VK et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-15550
20. Dieterich LC Mellberg S Langenkamp E et al. Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFbeta2 in vascular abnormalization. J Pathol. 2012;228:378-390
21. Watanabe T Nobusawa S Kleihues P Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153
22. Persson AI Petritsch C Swartling FJ et al. Non-stem cell origin for oligodendroglioma. Cancer Cell. 2010;18:669-682
23. Brown R Zlatescu M Sijben A et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res. 2008;14:2357-2362
24. Jenkinson MD Smith TS Brodbelt AR Joyce KA Warnke PC Walker C. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging. 2007;26: 1405-1412
25. LawM Brodsky JE Babb J et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging. 2007;25:1113-1119
26. Whitmore RG Krejza J Kapoor GS et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg. 2007;107:600-609
27. Narang J Jain R Scarpace L et al. Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: An analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors. J Neurooncol. 2011;102:287-293
28. Chawla S Krejza J Vossough A et al. Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol. 2013;34:1542-1549
29. Fellah S Caudal D De Paula AM et al. Multimodal MR imaging (diffusion perfusion and spectroscopy): Is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?. AJNR Am J Neuroradiol. 2013;34: 1326-1333
30. Choi C Ganji SK DeBerardinis RJ et al. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18:624-629
31. Elkhaled A Jalbert LE Phillips JJ et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4:116ra115
32. Bigner SH Rasheed BK Wiltshire R McLendon RE. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol. 1999;1:52-60
33. Godfraind C Rousseau E Ruchoux MM Scaravilli F Vikkula M. Tumour necrosis andmicrovascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol. 2003;29:462-471
34. Kawagishi H Nakamura H Maruyama M et al. ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res. 2010;70:4749-4758
35. Harada H Nakagawa K Iwata S et al. Restoration of wild-Type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 1999;59: 3783-3789
36. McKeller RN Fowler JL CunninghamJJ et al. The Arf tumor suppressor gene promotes hyaloid vascular regression During mouse eye development. Proc Natl Acad Sci U S A. 2002;99:3848-3853
37. Alhaja E Adan J Pagan R et al. Anti-migratory and anti-Angiogenic effect of p16: A novel localization at membrane ruffles and lamellipodia in endothelial cells. Angiogenesis. 2004;7:323-333
38. Zhang J Lu A Li L Yue J Lu Y. P16 modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest. 2010;28:588-597
39. Takeuchi H Ozawa S Shih CH et al. Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. Int J Cancer. 2004;109: 483-490
40. Gibson SL Dai CY Lee HW et al. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res. 2003;63: 742-746
41. Gerald D Chintharlapalli S Augustin HG Benjamin LE. Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013;73:1649-1657
42. Liu Y Carson-Walter EB Cooper A Winans BN Johnson MDWalter KA. Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J Neurooncol. 2010;99:13-24
43. Kao YC Jiang SJ Pan WA et al. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor. PLoS One. 2012;7: E51647
44. Hwang-Bo J Yoo KH Park JH Jeong HS Chung IS. Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis. Int J Cancer. 2012;131:298-309
45. ReedMJ Koike TSadounESageEHPuolakkainenP. InhibitionofTIMP1 enhances angiogenesis in vivoandcell migration in vitro. MicrovascRes. 2003;65:9-17
46. Zhang W Zhang X Lu H Matsukura M Zhao J Shinohara M. Silencing heme oxygenase-1 gene expression in retinal pigment epithelial cells inhibits proliferation migration and tube formation of cocultured endothelial cells. Biochem Biophys Res Commun. 2013;434:492-497
47. Marchio S Lahdenranta J Schlingemann RO et al. AminopeptidaseAis a functional target in angiogenic blood vessels. Cancer Cell. 2004;5: 151-162
48. Idbaih A Ducray F Sierra Del Rio M Hoang-Xuan K Delattre JY. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: Growth factor receptors and angiogenesis inhibitors. Oncologist. 2008;13:978-992
49. NewmanAC ChouWWelch-Reardon KM et al. Analysis of stromal cell secretomes reveals a critical role for stromal cell-derived hepatocyte growth factor and fibronectin in angiogenesis. Arterioscler Thromb Vasc Biol. 2013;33:513-522
50. Franchini M Frattini F Crestani S Bonfanti C Lippi G. von Willebrand factor and cancer: A renewed interest. Thromb Res. 2013;131: 290-292
51. Sasaki T Larsson H Tisi D Claesson-Welsh L Hohenester E Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties tissue distribution and anti-Angiogenic activity. J Mol Biol. 2000;301:1179-1190
52. Bernatchez PN Acevedo L Fernandez-Hernando C et al. Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem. 2007;282:30745-30753
53. Moreno MJ Ball M Rukhlova M et al. IGFBP-4 Anti-Angiogenicand Anti-Tumorigenic Effects Are Associated with Anti-Cathepsin B Activity. Neoplasia. 2013;15:554-567
54. Holroyd EW White TA Pan S Simari RD. Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure. Front Biosci (Elite Ed). 2012;4:392-400
55. Sabatel C Cornet AM Tabruyn SP et al. Sprouty1 a new target of the angiostatic agent 16K prolactin negatively regulates angiogenesis. Mol Cancer. 2010;9:231.